Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
This bill amends the Federal Food, Drug, and Cosmetic Act to create a clearer, more predictable process for applications to switch drugs from prescription (Rx) to nonprescription (OTC) status. It authorizes sponsors to request meetings with the FDA to plan switch applications and requires the Secretary to issue guidance within 18 months describing evidentiary expectations, use of published and unpublished data, meeting procedures, consumer self-selection evidence, and how digital tools can support labeling.
Safety vs access: progressives emphasize consumer safety, equity, and post-market surveillance; conservatives emphasize expanded access and market efficiency.
Relative to its intended legislative type, this bill is a focused administrative measure that clearly amends the FD&C Act to create defined procedures and deadlines to increase clarity for Rx-to-nonprescription switch applications, while also adding a GAO evaluation as a reporting complement.
This bill amends the Federal Food, Drug, and Cosmetic Act to create a clearer, more predictable process for applications to switch drugs from prescription (Rx) to nonprescription (OTC) status.
It authorizes sponsors to request meetings with the FDA to plan switch applications and requires the Secretary to issue guidance within 18 months describing evidentiary expectations, use of published and unpublished data, meeting procedures, consumer self-selection evidence, and how digital tools can support labeling.
The bill directs the FDA to publish a stakeholder engagement plan within one year to identify candidate prescription drugs for potential switches, defines full and partial Rx-to-nonprescription switches, and preserves existing OTC monograph authority and confidentiality protections.
On content alone this is a narrowly focused, technocratic bill with low fiscal impact and limited ideological baggage — features that historically increase the chance of enactment. Requirements (guidance, meetings, stakeholder plan, GAO study) are administratively oriented and preserve existing authorities, making bipartisan support plausible. The principal hurdles are legislative calendar pressure, potential procedural delays, and whether committees prioritize the measure; these reduce but do not eliminate the chance of becoming law.
Relative to its intended legislative type, this bill is a focused administrative measure that clearly amends the FD&C Act to create defined procedures and deadlines to increase clarity for Rx-to-nonprescription switch applications, while also adding a GAO evaluation as a reporting complement.
Safety vs access: progressives emphasize consumer safety, equity, and post-market surveillance; conservatives emphasize expanded access and market efficiency.
These are examples from the analysis, not a ranked list of the most-affected groups.
Safety vs access: progressives emphasize consumer safety, equity, and post-market surveillance; conservatives emphasize expanded access and market efficiency.
A mainstream progressive would likely view the bill as a procedural reform with some potential public-interest benefits (greater access, affordability) but would be cautious about patient safety, equity of access, and adequate evidentiary standards.
They would welcome clearer FDA guidance and stakeholder engagement but want strong consumer-protection provisions (e.g., robust evidence consumers can self-select and use drugs safely, attention to vulnerable populations).
They would also welcome the GAO review as oversight but may be skeptical that process changes primarily benefit industry unless safeguards are explicit.
A pragmatic moderate would likely view the bill favorably as a common-sense effort to clarify regulatory expectations and reduce uncertainty for sponsors while preserving FDA authority and confidentiality.
They would appreciate the deadlines for guidance and stakeholder engagement and see the GAO review as a useful accountability measure.
Their support would depend on whether the guidance strikes a balanced evidence standard that protects consumers without imposing needless delays.
A mainstream conservative would likely welcome measures that make it easier and more predictable for companies to move drugs to OTC status, viewing this as increased consumer choice, market dynamism, and potential cost savings.
They would appreciate that the bill focuses on process clarity rather than creating new regulatory barriers, preserves agency authority, and prohibits disclosure of trade secrets.
Their main concerns would be any added bureaucracy or unfunded mandates, but overall they would see the bill as market-friendly and pro-access.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone this is a narrowly focused, technocratic bill with low fiscal impact and limited ideological baggage — features that historically increase the chance of enactment. Requirements (guidance, meetings, stakeholder plan, GAO study) are administratively oriented and preserve existing authorities, making bipartisan support plausible. The principal hurdles are legislative calendar pressure, potential procedural delays, and whether committees prioritize the measure; these reduce but do not eliminate the chance of becoming law.
The bill has not accumulated any surfaced votes yet.
Safety vs access: progressives emphasize consumer safety, equity, and post-market surveillance; conservatives emphasize expanded access and…
On content alone this is a narrowly focused, technocratic bill with low fiscal impact and limited ideological baggage — features that histo…
Relative to its intended legislative type, this bill is a focused administrative measure that clearly amends the FD&C Act to create defined procedures and deadlines to increase clarity for Rx-to-nonprescription switch a…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.